Additional file 1: of Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression

Table S1. Minimum criteria required for the diagnosis of IBC. Table S2. Correlation between PD-L1 and clinicopathological tumour characteristics. Table S3. A logistic multivariate model for PD-L1 expression on immune cells. Table S4. Patient and tumour characteristics of the nIBC control group. Table S5. Frequencies of organ-specific metastases. Table S6. Patient and tumour characteristics of the IBC validation cohort from Marseille. Figure S1. Neo-adjuvant chemotherapy regimens. Figure S2. Kaplan-Meier curves of RFS and OS in the total IBC population (143 patients). Figure S3. Kaplan-Meier curves of significant prognostic variables for RFS. Figure S4. Kaplan-Meier curves of significant prognostic variables for DMFS. Figure S5. Kaplan-Meier curve showing significant survival benefit for HER2-positive IBC patients that received trastuzumab. Figure S6. Clinicopathological characteristics of the validation cohort. Figure S7. PD-L1 immunoreactivity and pCR in the validation cohort. Figure S8. Prognostic clinicopathological variables in the validation cohort. Figure S9. PD-L1 antigenicity decreases over time. (DOCX 10547Â kb